Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cadila Pharmaceuticals, India, has deferred its plans to construct a manufacturing plant at Rwanda, central Africa, in collaboration with US based Holtzman Group.
Subscribe to our email newsletter
Cadila Pharmaceuticals chairman I A Modi was quoted by Business Standard as saying that the company is in a wait-and-watch mode regarding the Rwanda project.
"No work has started on ground. We will take a call at the appropriate time," Modi added.
The proposed $65m facility was likely to produce solids, tablets and capsules; liquids, gels, ointments, creams and syrups; biologicals, injectables and vaccines and active pharmaceutical ingredients (APIs).
The plant was expected to be fully operational by 2015.